Intellia Therapeutics Stock Fair Value – INTELLIA THERAPEUTICS Reports Q3 Earnings Results for FY2023 as of September 30 2023
November 26, 2023
🌥️Earnings Overview
On November 9, 2023, INTELLIA THERAPEUTICS ($NASDAQ:NTLA) released their financial results for the third quarter of the fiscal year 2023, which ended on September 30, 2023. Total revenue for the quarter was USD 12.0 million, a decrease of 9.6% from the same period in the previous fiscal year. Net income for this quarter was USD -122.2 million, in comparison to a net loss of USD -113.2 million in the same period of the preceding year.
Share Price
On Thursday, INTELLIA THERAPEUTICS reported its Q3 earnings results for the fiscal year 2023, ending on September 30 2023. The company’s stock opened at $28.5 and closed at $25.0, reflecting a 12.3% plunge from the previous closing price of 28.4. This marks a significant decrease in stock prices as compared to the previous quarter, which had seen an increase in stock prices and positive results. While the results were not as good as expected, it is still worth noting that INTELLIA THERAPEUTICS is showing some signs of recovery, despite the challenging conditions posed by the pandemic. The company is now focusing on increasing its research and development efforts in order to develop new therapies that could potentially be used for a range of diseases.
The company is also looking to expand its collaborations with other biotech companies and venture capital firms in order to bring in new sources of capital and technology. The company has also started looking for potential strategic acquisitions in order to increase its market share and profitability. While the company saw a decrease in revenue and cash flow, it is still showing signs of recovery and looking to grow its business through various initiatives. Investors are advised to keep an eye on the company in order to monitor its progress in the coming quarters. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Intellia Therapeutics. More…
| Total Revenues | Net Income | Net Margin |
| 51.77 | -462.44 | -882.7% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Intellia Therapeutics. More…
| Operations | Investing | Financing |
| -390.9 | -107.44 | 529.6 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Intellia Therapeutics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 1.24k | 205.94 | 11.64 |
Key Ratios Snapshot
Some of the financial key ratios for Intellia Therapeutics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| -6.0% | – | -937.9% |
| FCF Margin | ROE | ROA |
| -786.8% | -28.3% | -24.4% |
Analysis – Intellia Therapeutics Stock Fair Value
At GoodWhale, we provide an in-depth analysis of INTELLIA THERAPEUTICS‘s fundamentals. Our proprietary Valuation Line calculates the intrinsic value of INTELLIA THERAPEUTICS’s stock to be around $67.9. This means that the current market price of $25.0 is undervalued by 63.2%. By analyzing INTELLIA THERAPEUTICS’s fundamentals with GoodWhale, you can make an informed decision on whether or not to invest in this company. More…
Peers
The company was founded in 2014 and is based in Cambridge, Massachusetts. Intellia has developed a platform that can be used to edit genes in a variety of cells and tissues. The company is also working on developing CRISPR-based treatments for diseases such as cancer and HIV. Intellia’s main competitors are CRISPR Therapeutics AG, Regeneron Pharmaceuticals Inc, and Editas Medicine Inc.
– CRISPR Therapeutics AG ($NASDAQ:CRSP)
Crispr Therapeutics AG is a biopharmaceutical company that focuses on the development of CRISPR/Cas9-based therapeutics for serious diseases. The company’s market cap as of 2022 is 4.28B and its ROE is -18.27%. Crispr Therapeutics AG was founded in 2013 and is headquartered in Zug, Switzerland.
– Regeneron Pharmaceuticals Inc ($NASDAQ:REGN)
Regeneron Pharmaceuticals Inc is a global biopharmaceutical company that discovers, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. The company’s products include EYLEA, Praluent, Dupixent, Libtayo, and Kevzara. As of 2021, the company had a market cap of $80.72 billion and a return on equity of 19.7%. Regeneron was founded in 1988 and is headquartered in Tarrytown, New York.
– Editas Medicine Inc ($NASDAQ:EDIT)
Editas Medicine Inc is a genome editing company based in Cambridge, Massachusetts. The company uses a technology called CRISPR to edit genes in order to treat genetic diseases. As of 2022, Editas Medicine Inc has a market cap of 886.02M and a Return on Equity of -23.75%. The company’s focus on genome editing makes it a leader in the field, and its market cap and ROE reflect this.
Summary
INTELLIA THERAPEUTICS reported their FY2023 Q3 earnings results on November 9, 2023, showing a 9.6% decrease in total revenue for the quarter compared to the previous year. Net income for this period was a net loss of -122.2 million compared to -113.2 million in the same period last year. This news caused the stock price to move down the same day, indicating that investors may be cautious when considering investment in INTELLIA THERAPEUTICS. Investors should research the company’s performance in comparison to its competitors and the industry as a whole to determine if this stock is a good fit for their portfolio.
Additionally, they should consider any potential risks associated with investing in the company.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
